![Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress](https://file.medchemexpress.com/product_pic/hy-16743a.gif)
Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress
![Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40261-023-01275-6/MediaObjects/40261_2023_1275_Fig1_HTML.png)
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
![PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers](https://www.researchgate.net/publication/344077664/figure/fig3/AS:937391233716224@1600502894438/Mean-SEM-remaining-of-glucosylceramide-GL-1-A-globostriaosylceramide-GL-3-B-and_Q320.jpg)
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
![Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/bb138c42-c42c-4521-bad7-85e5394342a9/cpdd865-fig-0001-m.jpg)
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library
![Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies](https://www.frontiersin.org/files/Articles/852003/fneur-13-852003-HTML/image_m/fneur-13-852003-g001.jpg)
Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
![Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0272638622010794-gr1.jpg)
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
![Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News](https://fabrydiseasenews.com/wp-content/uploads/2021/08/ClinicaltrialGraph.png)
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News
![The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2590059522001601-gr1.jpg)
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
![PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers](https://i1.rgstatic.net/publication/344077664_Pharmacokinetics_Pharmacodynamics_Safety_and_Tolerability_of_Oral_Venglustat_in_Healthy_Volunteers/links/5f65bc6792851c14bc86dca4/largepreview.png)
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
![Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-00404-5/MediaObjects/41598_2021_404_Fig3_HTML.png)
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
![Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7035220/bin/415_2020_9705_Fig1_HTML.jpg)
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC
![Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers](https://pub.mdpi-res.com/biomolecules/biomolecules-10-00335/article_deploy/html/images/biomolecules-10-00335-g001.png?1583581925)